Drug major Ranbaxy Laboratories has entered into a deal with South Korean biotech firm Medy-Tox for marketing its cosmetic product, Neuronox, in the Indian market.
Ranbaxy said it has entered into a strategic in-licensing agreement with Medy-Tox Inc and the introduction of the product would strengthen the company's presence in the dermatological segment.
In India, the current market size for this drug is about Rs 30 crore per annum.
"Neuronox comes as a welcome alternative to dermatologists in India and we aim to make botulinum toxin therapy more accessible and affordable to people in the country," Ranbaxy's Senior Vice President & Regional Director -- Asia & CIS -- Sanjeev Dani said in a statement.
Shares of Ranbaxy were trading at Rs 358.25, up 0.90 per cent, in the afternoon trade on the Bombay Stock Exchange.
Chaos is inherent in all compounded things. Strive on with diligence.
-- Buddha
POWERED BY
ePaper
02:22PM Saturday February 4,2012
- Scrapping 2G licences will help rebuild India’s image
As with its verdict in the Vodafone case two weeks ago, the Supreme Court’s latest decision to cancel all 2G licences will have a positive impact on
Financial Chronicle on Facebook
 Limited.JPG)
Post new comment